Compare NAKA & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAKA | PYXS |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.1M | 141.3M |
| IPO Year | 2023 | 2021 |
| Metric | NAKA | PYXS |
|---|---|---|
| Price | $7.48 | $1.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $13.33 | $8.67 |
| AVG Volume (30 Days) | 172.5K | ★ 1.1M |
| Earning Date | 11-18-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.19 | 3.03 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $13,858,000.00 |
| Revenue This Year | $3,833.87 | N/A |
| Revenue Next Year | N/A | $14,188.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.33 | $1.03 |
| 52 Week High | $840.00 | $5.55 |
| Indicator | NAKA | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 42.75 | 29.64 |
| Support Level | $4.17 | $1.58 |
| Resistance Level | $7.59 | $1.69 |
| Average True Range (ATR) | 0.75 | 0.12 |
| MACD | -0.19 | 0.00 |
| Stochastic Oscillator | 14.00 | 9.32 |
Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets. The firm has two principal business segments: Bitcoin Operations, which houses its Bitcoin treasury and is utilized to support investments in other Bitcoin-related companies; Healthcare Operations, which provides a patient-focused healthcare experience that provides patients personalized solutions in order to reduce opioid use and improve health outcomes. The company generates the majority of its revenue from the Healthcare Operations.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.